Applied Filters
What 2020 means for the life sciences
Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.
Pricing, patents and the PMPRB in Canada
Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.
The doctrine of equivalents in the medtech arena
The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.
Why Santen ends Neurim-style SPCs
In a boost for generic pharma companies, a U-turn by the EU’s highest court removed protection for repurposed active substances, as Robert Stephen and Gareth Morgan of CMS Cameron McKenna Nabarro Olswang explain.
The right recipe for the repurposing omelette
Big Pharma is looking for solutions to the COVID-19 pandemic wherever it can find them, so drug repurposing is more important than ever, as research lawyers Jakob Wested and John Liddicoat argue.
No SPC crown for Royalty Pharma
An attempt to obtain a supplementary protection certificate ended up raising the bar to achieving this coveted IP, as Joel Beevers and Michael Pears of Potter Clarkson explain.
Could good intentions lead to future danger?
The rush to open access to IP-protected tech, medicines and devices in the fight against COVID-19 could cause problems later, argues MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch.
SPCs: a deep dive into CJEU case law
The CJEU’s many attempts to clarify the law around SPCs has created more questions than answers, as Katie Cambrook and Ben Millson of Bristows explain.
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity
The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
